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ABSTRACT 1 
The ongoing spread of multidrug-resistant bacteria demands an intensive search for new 2 
antibacterial agents. In the present study, a series of new 1,3-thiazolidin-4-ones has been 3 
synthesized and investigated for its in vitro antibacterial activity. The most potent antibacterial 4 
compound 4c was found to be active, at low micromolar range, against Staphylococcus aureus, 5 
Staphylococcus epidermidis, Enterococcus faecalis and the pneumonic plague causative agent 6 
Yersinia pestis with minimum inhibitory concentrations of 5 µM, 2.5 µM, 2.5 µM and 5 µM, 7 
respectively. Compound 4c showed the ability to kill E. faecalis JH212 strain with a minimum 8 
bactericidal concentration of 5 µM. Furthermore, compounds 9b and 10a inhibited the biofilm 9 
formation in S. epidermidis, where they showed 70% to 80% inhibition at a concentration of 40 10 
µM. 11 
 12 
 13 
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 1 
INTRODUCTION 2 
Currently, infectious diseases are the second leading cause of death worldwide. Bacterial resistance 3 
against antibiotics is an increasing health problem in both community and hospital setting. It has a 4 
noteworthy impact on the mortality rates, morbidity rates and the financial burden associated. 5 
Although various novel antibacterial drugs had been introduced into the market in the past decades, 6 
the prevalence of multidrug-resistant pathogens remains among the major health problems which 7 
raises severe concern around the globe (Bassetti et al., 2013; Butler et al., 2013; Kumarasamy et al., 8 
2010; Lewis, 2013; Pendleton et al., 2013). 9 
Staphylococci and Enterococci are Gram-positive bacteria that are responsible for several 10 
community and hospital acquired infections. Staphylococcus aureus causes a wide range of 11 
infections from simple skin and soft tissue infections to serious illnesses like pneumonia, infective 12 
endocarditis and sepsis (Tong et al., 2015; Valour et al., 2013).  Staphylococcus epidermidis is 13 
regarded as the most frequent cause of nosocomial and indwelling medical device-associated 14 
infections. It causes more persistent infections due to its high ability to resist antibiotic treatments 15 
through biofilm formation (Gomes et al., 2014; Namvar et al., 2014; Otto, 2009).  16 
Since the beginning of the antibiotic era, the isolation of multidrug resistant enterococci has 17 
become increasingly common in hospital setting. Enterococcus faecalis and Enterococcus faecium 18 
are the most predominant species, cultured from humans, representing more than 90% of clinical 19 
isolates. E. faecalis infective endocarditis is still a very serious disease, associated with the 20 
presence of highly gentamicin-resistant strains and in-hospital mortality rates around 20% 21 
(Courvalin, 2006; Dahl and Bruun, 2013; de Perio et al. , 2006; Deshpande et al., 2007). On the 22 
other hand, the gram-negative bacterium Yersinia pestis is the causative agent of pneumonic 23 
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plague; which is the most severe manifestation of plague. The mortality rates of pneumonic plague 1 
are approximately 100% in untreated cases (Pechous et al., 2015). 2 
1,3-Thiazolidin-4-ones are a class of compounds that have shown potential as antibacterials 3 
(Aridoss et al., 2009; Gopalakrishnan et al., 2009; Jain et al., 2012; Poyraz et al., 2013; Sayyed et 4 
al., 2006; Verma and Saraf, 2008; Vicini et al., 2006; Vicini et al., 2008). Thiazolidin-4-ones have 5 
been found as inhibitors of the bacterial enzyme MurB; a key enzyme responsible for the synthesis 6 
of peptidoglycan (Andres et al., 2000). In this study, a series of 2-(arylimino)thiazolidin-4-ones and 7 
2-(benzylidenehydrazono)-3-arylthiazolidin-4-ones was synthesized. The synthesized compounds 8 
were tested for their in vitro antibacterial activity against selected clinically important pathogenic 9 
microbes. 10 
 11 
RESULTS AND DISCUSSION 12 
Chemistry  13 
The synthesis of the target 1,3-thiazolidin-4-one derivatives started with the conversion of the 14 
commercially available sulfanilamide 1 into the corresponding thioureido derivatives 2a-c (Roth 15 
and Degering, 1945)
 
when sulfanilamide 1 reacted with the appropriate isothiocyanate derivative 16 
(Scheme 1). The thioureido derivatives 2a-c were then refluxed with an equimolar amount of 17 
chloroacetic acid in glacial acid to give the respective 4-(4-oxo-3-substitutedthiazolidin-2-18 
ylideneamino)benzenesulfonamide derivatives 3a-c (Scheme 1). IR spectra of compounds 3a-c 19 
revealed strong characteristic intense bands at 1712-1724 cm
-1
 which correspond to the carbonyl 20 
group of the 1,3-thiazolidin-4-one ring. 
1
H-NMR spectra of compounds 3a-c displayed singlets at 21 
4.04-4.16 ppm for the two protons of the methylene (-CH2-) of the 1,3-thiazolidin-4-one nucleus. 22 
13
C-NMR spectra of compounds 3a-c exhibited new signals at 29.07-32.74 ppm, ascribed to the 23 
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methylene group, confirming the intramolecular cyclization and formation of the 1,3-thiazolidin-4-1 
one ring.  2 
Similarly, compounds 4a-c were synthesized by refluxing the thioureido derivatives 2a-c with an 3 
equimolar amount of diethyl bromomalonate in glacial acid (Scheme 1). IR spectra of the 4 
compounds 4a-c were characterized by the presence of two strong bands corresponding to the 5 
carbonyl group of the ethylester moiety and the carbonyl group of the 1.3-thiazolidin-4-one ring at 6 
1689-1751 cm
-1
. 
1
H-NMR spectra of compounds 4a-c exhibited triplets and quartets corresponding 7 
to the ethylester substituent at position 5. The synthesis of compounds 5a-c was attained by 8 
refluxing the corresponding thioureido derivatives 2a-c with an equimolar amount of maleic 9 
anhydride in glacial acid (Scheme 1). IR spectra of the 2-(4-oxothiazolidin-5-yl)acetic acid 10 
derivatives 5a-c showed two bands representing the carbonyl group of the 1,3-thiazolidin-4-one 11 
nucleus and the carbonyl group of the acetic acid moiety at 1660-1708 cm
-1
. 12 
The 4-isothiocyanatobenzenesulfonamide 6 was obtained by stirring a solution of sulfanilamide 1 in 13 
distilled water containing an equimolar amount of thiophosgen (El-Gaby et al., 2009). Compound 6 14 
was then stirred with an excess amount of hydrazine hydrate to give N-(4-sulfamoylphenyl)-15 
hydrazinecarbothioamide 7 (Sriram et al., 2009). The Schiff’s bases 8a,b were prepared by 16 
refluxing compound 7 with an equimolar amount of the appropriate aldehyde in methanol (Scheme 17 
2). 
1
H-NMR spectrum of compound 8a displayed signals at 10.32 and 12.05 ppm, which were 18 
exchangeable in D2O, confirming the presence of two NH groups of the hydrazinecarbothioamide. 19 
The 
13
C-NMR spectrum of compound 8b was characterized by the appearance of a new signal at 20 
39.66 ppm ascribed to the two carbon atoms of the N(CH3)2 group.  21 
Additionally, 
1
H-NMR spectra of compounds 8a,b exhibited signals at 8.15 and 8.06 ppm, 22 
respectively, for the imine proton of (N=CH). In a similar way to the synthetic pathway of the 23 
target 1,3-thiazolidin-4-ones outlined in Scheme 1, the 2-(4-(substituted)benzylidene)-N-(4-24 
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sulfamoylphenyl)-hydrazinecarbothioamides 8a,b were cyclized into the corresponding 1,3-1 
thiazolidin-4-one derivatives 9a,b by reaction with an equimolar amount of monochloroacetic acid 2 
(Scheme 2). IR spectra of compounds 9a,b revealed characteristic bands at 1732, 1697 cm
-1
, 3 
respectively, which correspond to the carbonyl group of the 1,3-thiazolidin-4-one ring. 
1
H-NMR 4 
spectra of compounds 9a,b displayed signals at 4.13 and 4.09 ppm, respectively, for the two 5 
protons of the methylene group of the 1,3-thiazolidin-4-one ring.  6 
In addition, 
1
H-NMR spectrum of compound 9b revealed a singlet at 2.97 ppm representing the 6 7 
protons of the dimethylamino group. The Schiff’s bases 8a,b were also cyclized into the 8 
corresponding 1,3-thiazolidin-4-one derivatives 10a,b, by refluxing with an equimolar amount of 9 
diethyl bromomalonate in glacial acetic acid (Scheme 2). IR spectra of compounds 10a,b showed 10 
two bands for the two carbonyl groups; the ethyl ester moiety and the 1,3-thiazolidin-4-one ring at 11 
1612-1739 cm
-1
. 
1
H-NMR spectra of compounds 10a,b exhibited triplets and quartets representing 12 
the ethyl group of the ethyl ester substituent at position 5.  13 
Finally, the synthesis of the 1,3-thaizolidin-4-one derivatives 11a,b was attained by refluxing the 14 
corresponding Schiff’s bases 8a,b, with an equimolar amount of maleic anhydride in glacial acetic 15 
acid (Scheme 2). 
1
H-NMR spectra of compounds 11a,b revealed new signals at 10.86 and 10.75 16 
ppm, respectively, corresponding to the one proton of the carboxylic OH group. 17 
To confirm the cyclization pattern of the 1,3-thiazolidin-4-one ring, compound 3a was subjected to 18 
x-ray crystallography measurement. Crystals suitable for X-ray diffraction were grown from 19 
dichloromethane solution by slow cooling. The structure could be determined in the triclinic space 20 
group P-1 with four symmetric independent molecules in the asymmetric unit (Z’ = 4). This is due 21 
to a break in symmetry by the disorder of the central phenyl rings. The bond lengths and angles are 22 
all within normal ranges (Allen et al., 1987). The molecules of 3a adopted two different 23 
conformations in this structure, with the angle between the thiazolidinone and the phenyl ring either 24 
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60° or -50° (Figure 1a). This has no influence on the overall packing and it is assumed that due to 1 
the comparable size of the phenyl ring and the sulfonamide terminal group, the phenyl ring can 2 
rotate rather freely. The crystal packing consists of pseudo-centrosymmetric dimers of 3a stabilized 3 
through weak C-H∙∙∙O hydrogen bonds (Figure 1b). These dimers are connected to the next dimer 4 
through N-H∙∙∙O hydrogen bonds, between the terminal amide group and the C=O group of the 5 
thiazolidinone rings, linking the structure together along the crystallographic b-axis. An additional 6 
N-H∙∙∙O hydrogen bond between the terminal amide group and the S=O group of the sulfonamide 7 
links the molecules along b. This packing results in the formation of stacks along the 8 
crystallographic a-axis which consist of alternate disordered and non-disordered molecules.  9 
 10 
Antibacterial activity  11 
All of the newly synthesized final compounds have been screened at a highest concentration of 40 12 
µM, for their in vitro antibacterial activity against selected clinically important pathogenic bacteria. 13 
These bacteria include the Gram-positive bacteria; S. aureus (Strains; 8325, HG001, MA12, RN1 14 
and Xen29), S. epidermidis (Strains; RP62A, 195 and 047), E. faecalis JH212, E.  faecium 6413 15 
and the Gram-negative bacteria; Escherichia coli 536, Pseudomonas aeruginosa, Y. pestis KUMA 16 
and Yersinia pseudotuberculosis 252 01A. Staphylococci, Enterococci and P. aeruginosa belong to 17 
the so called “ESKAPE” pathogens; pathogenic bacteria that are responsible for the highest impact 18 
in bacterial resistance (Pendleton et al., 2013). Moreover, S. aureus, S. epidermidis, P. aeruginosa, 19 
and E. coli can cause persistent infections that are resistant to antibiotic treatments due to their 20 
ability to form biofilm (Romling and Balsalobre, 2012).  21 
All the tested compounds have been evaluated for their in vitro antibacterial activity by measuring 22 
the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). 23 
MIC is the lowest concentration of the tested compound that inhibits the visible growth of the tested 24 
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bacterial strain after overnight incubation while MBC is the lowest concentration of the tested 1 
compound required to kill the tested bacterium. Antibacterial agents are usually considered   2 
bactericidal if the MBC value doesn’t exceed four folds the MIC value (French, 2006). All the 3 
tested compounds showed MIC values higher than 40 µM except compounds 4a and 4c. 4 
Gentamicin and tetracycline were used in the test as reference drugs. The antibacterial activities of 5 
compounds 4a and 4c are presented in Table 1. 6 
Based on the results, mentioned in Table 1, it was found that the presence of ethylester at position 5 7 
on the 1,3-thiazolidin-4-one ring is an essential feature for activity whereas the other congeners 8 
with 5-unsubstituted (compounds 3a-c) or 5-acetic acid side chain (compounds 5a-c) are devoid of 9 
activity. However, the nature of the substituent at position 3 was also critical for keeping compound 10 
activity as only the methyl and the phenyl substituents (compounds 4a and 4c, respectively) were 11 
able to maintain the antibacterial activity. This was evidenced by compound 4b in which extending 12 
the methyl into ethyl led to complete loss of activity (compound 4a compared to compound 4b). 13 
Generally; compound 4c, with a phenyl substitution at position 3 of the 1,3-thiazolidin-4-one 14 
nucleus, showed lower MIC values when compared with the MIC values of compound 4a with the 15 
3-methyl substituent. In fact, in most cases, compound 4c showed a double potency compared to 16 
compound 4a. The higher activity of the more lipophilic ethylester derivatives 4a and 4c compared 17 
to the carboxylic acid derivatives 5a and 5c might be due to their higher ability to penetrate the 18 
bacterial outer membrane. Additionally, these ethylester derivatives might act as prodrugs which 19 
enhance the penetration of their carboxylic acid counterparts. However, this requires further 20 
investigations by testing the major form of the compounds existing in the bacterial cells after 21 
penetration of the compounds. 22 
Compound 4c exhibited MIC values ranging from 5 to 20 µM against five different S. aureus 23 
strains and MIC values ranging from 2.5 to 10 µM against three different S. epidermidis strains. 24 
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Compound 4c also showed an antibacterial activity against E. faecalis with MIC value of 2.5 µM 1 
and MBC value of 5 µM. The potency of compound 4c against E. faecalis is significantly high 2 
when compared to the reference drug gentamicin, MIC value of gentamicin= 26.2 µM, showing 3 
that this compound is a potent bactericidal. 4 
Most importantly, compounds 4a and 4c revealed antibacterial activity, not only against different 5 
Gram-positive pathogens, but also against the Gram-negative bacterium Y. pestis KUMA with MIC 6 
values of 10 µM and 5 µM, respectively. On the other hand, none of the 2-(benzylidenehydrazono)-7 
3-arylthiazolidin-4-one derivatives, described in Scheme 2, showed antibacterial activity. 8 
 9 
Inhibition of biofilm formation  10 
Many microbes form biofilm in response to many factors in which cells stick to each other on a 11 
surface. These adherent cells are frequently embedded within a self-produced matrix of 12 
extracellular polymeric substance. The factors, by which biofilm is formed, may include cellular 13 
recognition of specific or non-specific attachment sites on a surface. In some cases, the factors 14 
include the exposure of planktonic cells to sub-inhibitory concentrations of antibiotics. Biofilms are 15 
a serious problem for public health because of the increased resistance of biofilm-associated 16 
microorganisms to antimicrobial agents and the potential for these microorganisms to cause 17 
infections in patients with indwelling medical devices (Hoffman et al., 2005; Karatan and Watnick, 18 
2009).  19 
Unlike the antibacterial activity, the 2-(benzylidenehydrazono)-3-arylthiazolidin-4-one derivatives 20 
9b and 10a were able to inhibit the biofilm formation in S. epidermidis, where they showed 70% to 21 
80% inhibition at a concentration of 40 µM. This highlighted the fact that this structure feature was 22 
crucial for biofilm inhibition activity. However, this was limited by the type of the substitution at 23 
position 4 of the 1,3-thiazolidin-4-one ring; where only the 4-unsubstituted derivative 9b and the 4-24 
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ethoxycarbonyl derivative 10a were active as biofilm formation inhibitors. Generally, the presence 1 
of the acetic acid side chain at position 5 of the thiazolidinone ring (compounds 5a-c and 11a,b) 2 
resulted in analogues, lacking both antibacterial and biofilm inhibition activity. 3 
 4 
CONCLUSION 5 
We report herein the synthesis of new 1,3-thiazolidin-4-one derivatives and their in vitro 6 
antibacterial activity. Based on the previous biological results, we can suggest that 1,3-thiazolidin-7 
4-one derivatives with an ethylester moiety at position 5 (compounds 4a and 4c) are good lead 8 
compounds for further biological evaluation as antibacterial agents. Compounds 4a and 4c were not 9 
only active against different Gram-positive pathogens, but also against the Gram-negative 10 
bacterium Y. pestis. The antibacterial activity of compounds 4a and 4c can be due to the potential 11 
MurB inhibition activity of the thiazolidin-4-one nucleus. In addition, compounds 9b and 10a 12 
revealed biofilm inhibition activity against S. epidermidis biofilm formation. These obtained results 13 
are encouraging for further synthesis of new 1,3-thiazolidin-4-one derivatives with different 14 
substitutions at positions 3 and 5, as potential antibacterial agents. 15 
 16 
EXPERIMENTAL 17 
Chemical syntheses 18 
Materials and methods 19 
1
H-NMR and 
13
C-NMR spectra were recorded on an Avance 400 nuclear magnetic resonance 20 
spectrometer, Bruker Biospin GmbH Rheinstetten, Germany (
1
H 400.123 MHz, 
13
C 100.613 MHz). 21 
As an internal standard, the signals of the deuterated solvents were used (DMSO-d6: 
1
H 2.5 ppm, 22 
13
C 39.43 ppm). The following abbreviations describing the multiplicity are used: (s) singlet, (d) 23 
doublet, (t) triplet, (q) quartet, (dd) doublet of doublet. IR spectra were obtained with a Biorad 24 
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PharmalyzIR FT-IR spectrometer (Biorad, Cambridge, MA, USA). Melting points were measured 1 
using an apparatus Sanyo Gallenkamp (Sanyo Gallenkamp, Loughborough, UK) and were not 2 
corrected. Elemental microanalyses were performed at the microanalytical center; Al-Azhar 3 
University, Cairo, Egypt. Thin layer chromatography (TLC) was carried out on TLC aluminum 4 
sheets, silica gel F254, (Merck KGaA, Darmstadt, Germany), and visualized in ultraviolet (UV) 5 
chamber. All chemicals were purchased from Sigma-Aldrich Chemicals (Deisenhofen, Germany), 6 
Acros Organics (Geel, Belgium) and VWR International (Darmstadt, Germany), and were used 7 
without further purification. 8 
General procedures for the synthesis of 4-(3-substitutedthioureido)benzenesulfonamides (2a-c)  9 
The appropriate isothiocyanate (12 mmol) was added to a solution of sulfanilamide 1 (10 mmol) in 10 
absolute ethanol (20 mL) then few drops of triethylamine were added to the solution and refluxed 11 
for 24 h. A white precipitate was formed, filtered off, dried and recrystallized from ethanol to give 12 
compounds 2a-c. 13 
4-(3-Methylthioureido)benzenesulfonamide (2a) 14 
Yield, 88%; m.p. 222-224 ˚C; IR, cm-1: 3313, 3294, 3132 (NH, NH2), 3055 (CH arom.), 2943, 2870 15 
(CH aliph.), 1249 (C=S), 1369, 1161 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 2.94 (d, 3H, CH3), 7.25 16 
(s, 2H, SO2NH2, exchangeable with D2O), 7.62 (d, 2H, J= 8.51 Hz, CHarom.), 7.74 (d, 2H, J= 8.95 17 
Hz, CHarom.), 7.97 (s, 1H, NH, exchangeable with D2O), 9.84 (s, 1H, NH, exchangeable with D2O). 18 
13
C-NMR (DMSO-d6, ppm) δ: 31.07 (CH3), 121.46, 126.21, 138.36, 142.59 (CHarom.), 180.98 19 
(C=S). 20 
4-(3-Ethylthioureido)benzenesulfonamide (2b) 21 
Yield, 92%; m.p. 209-211 ˚C; IR, cm-1: 3352, 3298, 3155 (NH, NH2), 3062 (CH arom.), 2974, 2890 22 
(CH aliph.), 1249 (C=S), 1377, 1165 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.19 (t, 3H, J= 7.91 Hz, 23 
CH3), 3.45 (q, 2H, J= 7.09 Hz, CH2), 7.23 (s, 2H, SO2NH2), 7.61 (d, 2H, J= 8.62 Hz, CHarom.), 7.73 24 
11 
 
(d, 2H, J= 8.9 Hz, CHarom.), 7.95 (s, 1H, NH), 9.82 (s, 1H, NH). 
13
C-NMR (DMSO-d6, ppm) δ: 1 
13.92 (CH3), 25.46 (CH2), 121.50, 126.21, 138.38, 142.69 (CHarom.), 179.99 (C=S). 2 
4-(3-Phenylthioureido)benzenesulfonamide (2c) 3 
Yield, 86%; m.p. 204-206 ˚C; IR, cm-1: 3344, 3240, 3165 (NH, NH2), 3008 (CH arom.), 1242 4 
(C=S), 1334, 1157 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 7.15 (dd, 1H, CHarom.), 7.28 (s, 2H, 5 
SO2NH2), 7.35 (dd, 2H, CHarom.), 7.49 (d, 2H, CHarom.), 7.70 (d, 2H, J= 8.73 Hz, CHarom.) 7.75 (d, 6 
2H, J= 8.61 Hz, CHarom.), 10.02 (s, 1H, NH), 10.05 (s, 1H, NH). 
13
C-NMR (DMSO-d6, ppm) δ: 7 
122.30, 122.49, 123.60, 124.63, 126.03, 128.43, 139.07, 142.57 (CHarom.), 179.48 (C=S). 8 
General procedures for the synthesis of 4-(4-oxo-3-substituted-thiazolidin-2-9 
ylideneamino)benzenesulfonamides (3a-c)  10 
10 mmol of monochloroacetic acid and a catalytic amount of anhydrous sodium acetate were added 11 
to a solution of compound 2a, 2b or 2c (10 mmol) in glacial acetic acid (20 mL). The mixture was 12 
refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered 13 
off and crystallized from ethanol to give the corresponding 1,3-thiazolidin-4-one derivatives 3a-c. 14 
4-(3-Methyl-4-oxo-thiazolidin-2-ylideneamino)benzenesulfonamide (3a) 15 
Yield, 58%; m.p. 183-185 ˚C; IR, cm-1: 3332, 3221 (NH2), 3097 (CH arom.), 2943, 2851 (CH 16 
aliph.), 1712 (C=O), 1620 (C=N), 1377, 1153 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 3.17 (s, 3H, N-17 
CH3), 4.06 (s, 2H, CH2), 7.09 (d, 2H, J= 8.51 Hz, CHarom.), 7.31 (s. 2H, SO2NH2, exchangeable 18 
with D2O), 7.80 (d, 2H, J= 8.82 Hz, CHarom.). 
13
C-NMR (DMSO-d6, ppm) δ: 29.07 (CH2), 32.74 19 
(CH3), 121.16, 127.06, 139.62, 151.12 (CHarom.), 156.89 (N=C), 171.80 (C=O). Anal. Calcd. For 20 
C10H11N3O3S2 (285.34): C, 42.09; H, 3.89; N, 14.73. Found: C, 42.21; H, 3.93; N, 14.90. 21 
4-(3-Ethyl-4-oxo-thiazolidin-2-ylideneamino)benzenesulfonamide (3b) 22 
Yield, 64%; m.p. 169-171 ˚C; IR, cm-1: 3329, 3255 (NH2), 3080 (CH arom.), 2983, 2860 (CH 23 
aliph.), 1732 (C=O), 1643 (C=N), 1373, 1168 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.21 (t, 3H, J= 24 
12 
 
7.11 Hz, CH3), 3.81 (q, 2H, J= 7.17 Hz, CH3), 4.04 (s, 2H, CH2), 7.09 (d, 2H, J= 8.49 Hz, CHarom.), 1 
7.31 (s. 2H, SO2NH2), 7.81 (d, 2H, J= 8.91 Hz, CHarom.). 
13
C-NMR (DMSO-d6, ppm) δ: 12.21 2 
(CH2CH3), 32.73 (CH2-C=O), 37.42 (CH2CH3), 121.25, 127.13, 139.71, 151.19 (CHarom.), 156.11 3 
(N=C), 171.64 (C=O). Anal. Calcd. For C11H13N3O3S2 (299.37): C, 44.13; H, 4.38; N, 14.04. 4 
Found: C, 44.22; H, 4.39; N, 14.15.  5 
4-(4-Oxo-3-phenylthiazolidin-2-ylideneamino)benzenesulfonamide (3c) 6 
Yield, 60%; m.p. 190-192 ˚C; IR, cm-1: 3363, 3204 (NH2), 3051 (CH arom.), 1724 (C=O), 1635 7 
(C=N), 1373, 1153 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 4.16 (s, 2H, CH2), 6.88 (d, 2H, CHarom.), 8 
7.09 (dd, 1H, CHarom.), 7.34 (dd, 2H, CHarom.), 7.42 (d, 2H, J= 8.88 Hz, CHarom.), 7.45 (s, 2H, 9 
SO2NH2), 7.53 (d, 2H, J= 8.97 Hz, CHarom.). 
13
C-NMR (DMSO-d6, ppm) δ: 32.74 (CH2), 122.55, 10 
124.09, 128.36, 128.89, 129.13, 135.19, 148.06, 155.78 (CHarom.), 171.54 (N=C), 172.57 (C=O). 11 
Anal. Calcd. For C15H13N3O3S2 (347.41): C, 51.86; H, 3.77; N, 12.10. Found: C, 51.98; H, 3.75; N, 12 
12.27. 13 
General procedures for the synthesis of ethyl 4-oxo-3-substituted-2-(4-14 
sulfamoylphenylimino)thiazolidine-5-carboxylates (4a-c) 15 
10 mmol of diethylbromomalonate and a catalytic amount of anhydrous sodium acetate were added 16 
to a solution of compound 2a, 2b or 2c (10 mmol) in glacial acetic acid (20 mL). The mixture was 17 
refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered 18 
off and crystallized from ethanol to give the corresponding 1,3-thiazolidin-4-one derivatives 4a-c.  19 
Ethyl 3-methyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidine-5-carboxylate (4a) 20 
Yield, 46%; m.p. 106-108 ˚C; IR, cm-1: 3356, 3255 (NH2), 3070 (CH arom.), 2978, 2870 (CH 21 
aliph.), 1724, 1698 (2C=O), 1369, 1157 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.25 (t, 3H, J= 7.21 22 
Hz, CH3), 3.19 (s, 3H, CH3), 3.72 (q, 2H, J= 7.03 Hz, CH2), 4.10 (s, 1H, CH), 7.09 (d, 2H, J= 8.63 23 
Hz, CHarom.), 7.32 (s, 2H, SO2NH2), 7.82 (d, 2H, J= 8.72 Hz, CHarom.). 
13
C-NMR (DMSO-d6, ppm) 24 
13 
 
δ: 13.52 (COOCH2CH3), 21.90 (N-CH3), 29.15 (HC-C=O), 32.81 (COOCH2CH3), 121.24, 127.14, 1 
139.70, 151.20 (CHarom.), 155.51 (N=C), 171.05 (COOCH2CH3), 171.89 (N-C=O). Anal. Calcd. For 2 
C13H15N3O5S2 (357.41): C, 43.69; H, 4.23; N, 11.76. Found: C, 43.77; H, 4.25; N, 11.85. 3 
Ethyl 3-ethyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidine-5-carboxylate (4b) 4 
Yield, 40%; m.p. 159-161 ˚C; IR, cm-1: 3544, 3461 (NH2), 3070 (CH arom.), 2989, 2877 (CH 5 
aliph.), 1751, 1721 (2C=O), 1390, 1198 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.13 (t, 3H, J= 7.18 6 
Hz, CH3), 1.19 (t, 3H, J= 7.34 Hz, CH3), 3.74 (q, 2H, J= 7.51 Hz, CH2), 3.84 (q, 2H, J= 7.42 Hz, 7 
CH2), 4.05 (s, 1H, CH), 7.09 (d, 2H, J= 8.59 Hz, CHarom.), 7.79 (s, 2H, SO2NH2), 7.84 (d, 2H, J= 8 
8.79 Hz, CHarom.). 
13
C-NMR (DMSO-d6, ppm) δ: 11.24 (CH3CH2), 13.41 (COOCH2CH3), 34.96 9 
(CH3CH2), 56.42 (HC-C=O), 64.21 (COOCH2CH3), 121.22, 127.44, 133.57, 140.57 (CHarom.), 10 
155.29 (N=C), 164.78 (COOCH2CH3), 168.96 (N-C=O). Anal. Calcd. For C14H17N3O5S2 (371.43): 11 
C, 45.27; H, 4.61; N, 11.31. Found: C, 45.39; H, 4.69; N, 11.46.  12 
Ethyl 4-oxo-3-phenyl-2-(4-sulfamoylphenylimino)thiazolidine-5-carboxylate (4c) 13 
Yield, 53%; m.p. 126-128 ˚C; IR, cm-1: 3356, 3259 (NH2), 3062 (CH arom.), 2981, 2871 (CH 14 
aliph.), 1728, 1701 (2C=O), 1369, 1153 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.23 (t, 3H, J= 7.65 15 
Hz, CH3), 4.21 (q, 2H, J= 7.71 Hz, CH2), 4.32 (s, 1H, CH), 6.87 (dd, 1H, CHarom.), 7.04 (dd, 2H, 16 
CHarom.), 7.29 (d, 2H, CHarom.), 7.41 (d, 2H, J= 8.80 Hz, CHarom.), 7.52 (s, 2H, SO2NH2), 7.76 (d, 17 
2H, J= 8.91 Hz, CHarom.). 
13
C-NMR (DMSO-d6, ppm) δ: 13.86 (COOCH2CH3), 28.62 (HC-C=O), 18 
32.75 (COOCH2CH3), 120.55, 120.94, 124.10, 127.02, 128.37, 128.90, 129.15, 129.54 (CHarom.), 19 
154.95 (N=C), 170.91 (COOCH2CH3), 171.50 (N-C=O). Anal. Calcd. For C18H17N3O5S2 (419.47): 20 
C, 51.54; H, 4.08; N, 10.02. Found: C, 51.63; H, 4.11; N, 10.09.  21 
14 
 
General procedures for the synthesis of 2-(4-oxo-3-substituted-2-(4-1 
sulfamoylphenylimino)thiazolidin-5-yl)acetic acids (5a-c) 2 
10 mmol of maleic anhydride was added to a solution of compound 2a, 2b or 2c (10 mmol) in 3 
glacial acetic acid (20 mL), The  mixture was refluxed for 24 h and left to cool then poured into 4 
crushed ice. The formed precipitate was filtered off and crystallized from ethanol to give the 5 
corresponding 1,3-thiazolidin-4-one derivatives 5a-c.  6 
2-(3-Methyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidin-5-yl)acetic acid (5a) 7 
Yield, 61%; m.p. 160-162 ˚C; IR, cm-1: 3356, 3205 (NH2), 3100 (OH), 3052 (CH arom.), 2985, 8 
2878 (CH aliph.), 1697, 1674 (2C=O), 1370, 1157 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.95 (d, 9 
2H, J= 6.52 Hz, CH2), 3.21 (s, 3H, CH3), 4.54 (t, 1H, J= 6.79 Hz, CH), 7.05 (d, 2H, J= 8.69 Hz, 10 
CHarom.), 7.71 (s, 2H, SO2NH2), 7.80 (d, 2H, J= 8.99 Hz, CHarom.), 10.56 (s, 1H, OH). 
13
C-NMR 11 
(DMSO-d6, ppm) δ: 21.03 (N-CH3), 29.19 (CH2), 43. 58 (HC-C=O), 118.39, 126.71, 138.53, 12 
151.32 (CHarom.), 156.89 (-N=C), 168.45 (COOH), 173.72 (C=O). Anal. Calcd. For C12H13N3O5S2 13 
(343.38): C, 41.97; H, 3.82; N, 12.24. Found: C, 42.08; H, 3.80; N, 12.38. 14 
2-(3-Ethyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidin-5-yl)acetic acid (5b) 15 
Yield, 61%; m.p. 188-190 ˚C; IR, cm-1: 3352, 3263 (NH2), 3113 (OH), 3052 (CH arom.), 2997, 16 
2865 (CH aliph.), 1701, 1658 (2C=O), 1334, 1157 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.21 (t, 3H, 17 
J= 7.33 Hz, CH3), 1.81 (d, 2H, J= 7.01 Hz, CH2), 3.80 (q, 2H, J= 7.64 Hz, CH2), 4.29 (t, 1H, J= 18 
6.91 Hz, CH), 7.09 (d, 2H, J= 8.90 Hz, CHarom.), 7.72 (s, 2H, SO2NH2), 7.78 (d, 2H, J= 9.0 Hz, 19 
CHarom.), 10.49 (s, 1H, OH). 
13
C-NMR (DMSO-d6, ppm) δ: 12.14 (CH3CH2), 22.36 (CH2), 38.45 20 
(CH3CH2), 43.50 (HC-C=O), 121.30, 127.07, 139.63, 141.52 (CHarom.), 155.93 (-N=C), 168.40 21 
(COOH), 172.97 (C=O). Anal. Calcd. For C13H15N3O5S2 (357.41): C, 43.69; H, 4.23; N, 11.76. 22 
Found: C, 43.77; H, 4.27; N, 11.83.  23 
15 
 
2-(4-Oxo-3-phenyl-2-(4-sulfamoylphenylimino)thiazolidin-5-yl)acetic acid (5c) 1 
Yield, 63%; m.p. 171-173 ˚C; IR, cm-1: 3348, 3300 (NH2), 3215 (OH), 3066 (CH arom.), 2931, 2 
2875 (CH aliph.), 1708, 1660 (2C=O), 1388, 1161 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.91 (d, 3 
2H, J= 6.64 Hz, CH2), 4.49 (t, 1H, J= 6.75 Hz, CH), 6.87 (dd, 1H, CHarom.), 7.03 (dd, 2H, CHarom.), 4 
7.29 (d, 2H, CHarom.), 7.46 (d, 2H, J= 8.92 Hz, CHarom.), 7.74 (s, 2H, SO2NH2), 7.95 (d, 2H, J= 8.83 5 
Hz, CHarom.), 10.35 (s, 1H, OH). 
13
C-NMR (DMSO-d6, ppm) δ: 21.02 (CH2), 43.62 (HC-C=O), 6 
120.71, 121.09, 122.93, 127.05, 128.47, 128.92, 129.18, 139.54 (CHarom.), 155.82 (-N=C), 168.86 7 
(COOH), 171.97 (C=O). Anal. Calcd. For C17H15N3O5S2 (405.45): C, 50.36; H, 3.73; N, 10.36. 8 
Found: C, 50.49; H, 3.71; N, 10.44.  9 
Synthesis of 4-isothiocyanatobenzenesulfonamide (6)  10 
A solution of sulfanilamide 1 in water was prepared by stirring sulfanilamide 1 (10 mmol) in 11 
distilled water (40 mL), containing hydrochloric acid (10 mmol), for 5 min. Thiophosgen (10 12 
mmol) was added to the prepared solution and the  mixture was stirred at room temperature for 2 h. 13 
The formed precipitate was filtered off and dried to give compounds 6 (El-Gaby et al., 2009). 14 
Synthesis of N-(4-sulfamoylphenyl)hydrazinecarbothioamide (7) 15 
A mixture, of compound 6 (10 mmol) and excess amount of hydrazine hydrate in isopropanol (40 16 
mL), was stirred at room temperature for 4 hours. The formed precipitate was filtered off and dried 17 
to give compound 7 (Sriram et al., 2009). 18 
General procedures for the synthesis of 2-(4-(substituted)benzylidene)-N-(4-19 
sulfamoylphenyl)hydrazinecarbothioamides (8a,b) 20 
A mixture, of compound 7 (10 mmol) and the appropriate aldehyde (10 mmol) in methanol (30 21 
mL), was refluxed for 5 h. The formed precipitate was filtered, while hot, and the obtained solid 22 
was dried to give compounds 8a,b. 23 
16 
 
2-(4-Chorobenzylidene)-N-(4-sulfamoylphenyl)hydrazinecarbothioamide (8a) 1 
Yield, 59%; m.p. 240-242 ˚C; IR, cm-1: 3288, 3245, 3131 (NH, NH2), 3089 (CH arom.), 2978, 2873 2 
(CH aliph.), 1587 (C=N), 1278 (C=S), 1393, 1158 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 6.70 (d, 3 
2H, J= 8.48 Hz, CHarom.), 7.25 (s, 2H, SO2NH2, exchangeable with D2O), 7.56 (d, 2H, J= 8.84 Hz, 4 
CHarom.), 7.82 (d, 2H, J= 8.74 Hz, CHarom.), 7.98 (d, 2H, J= 8.72 Hz, CHarom.), 8.15 (s, 1H, -N=CH), 5 
10.32 (s, 1H, NH, exchangeable with D2O), 12.05 (s, 1H, NH, exchangeable with D2O). 
13
C-NMR 6 
(DMSO-d6, ppm) δ: 125.42, 125.63, 129.07, 130.00, 132.82, 134.63, 140.35, 142.01 (CHarom.), 7 
142.15 (N=CH), 175.93 (C=S). Anal. Calcd. For C14H13ClN4O2S2 (368.86): C, 45.59; H, 3.55; N, 8 
15.19. Found: C, 45.65; H, 3.58; N, 15.32.  9 
2-(4-(Dimethylamino)benzylidene)-N-(4-sulfamoylphenyl)hydrazinecarbothioamide (8b) 10 
Yield, 55%; m.p. 225-227 ˚C; IR, cm-1: 3333, 3245, 3135 (NH, NH2), 3090 (CH arom.), 2974, 2899 11 
(CH aliph.), 1587 (C=N), 1268 (C=S), 1364, 1154 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 2.98 (s, 6H, 12 
N(CH3)2), 6.73 (d, 2H, J= 8.51 Hz, CHarom.), 7.32 (s, 2H, SO2NH2), 7.70 (d, 2H, J= 8.56 Hz, 13 
CHarom.), 7.78 (d, 2H, J= 8.81 Hz, CHarom.), 7.86 (d, 2H, J= 8.89 Hz, CHarom.), 8.06 (s, 1H, -N=CH), 14 
10.10 (s, 1H, NH), 11.76 (s, 1H, NH). 
13
C-NMR (DMSO-d6, ppm) δ: 39.66 (N(CH3)2), 111.50, 15 
120.82, 124.67, 125.50, 129.08, 139.77, 142.15, 151.55 (CHarom.), 144.55 (N=CH), 174.47 (C=S). 16 
Anal. Calcd. For C16H19N5O2S2 (377.48): C, 50.91; H, 5.07; N, 18.55. Found: C, 50.99; H, 5.12; N, 17 
18.71. 18 
General procedures for the synthesis of 4-(2-(4-(substituted)benzylidene)hydrazono)-4-19 
oxothiazolidin-3-yl)benzenesulfonamides (9a,b) 20 
10 mmol of monochloroacetic acid and a catalytic amount of anhydrous sodium acetate were added 21 
to a solution of compound 8a or 8b (10 mmol) in glacial acetic acid (20 mL). The mixture was 22 
refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered 23 
off and crystallized from ethanol to give the corresponding 4-thiazolidinone derivatives 9a,b.  24 
17 
 
4-(2-(4-Chlorobenzylidene)hydrazono)-4-oxothiazolidin-3-yl)benzenesulfonamide (9a) 1 
Yield, 53%; m.p. 288-290 ˚C; IR, cm-1: 3346, 3261 (NH2), 3062 (CH arom.), 2969, 2885 (CH 2 
aliph.), 1732 (C=O), 1620 (C=N), 1393, 1156 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 4.13 (s, 2H, 3 
CH2), 7.39 (d, 2H, J= 8.78 Hz, CHarom.), 7.50 (s, 2H, SO2NH2, exchangeable with D2O), 7.54 (d, 4 
2H, J= 8.66 Hz, CHarom.), 7.72 (d, 2H, J= 8.94 Hz, CHarom.), 7.89 (d, 2H, J= 8.52 Hz, CHarom.), 8.30 5 
(s, 1H, N=CH). 
13
C-NMR (DMSO-d6, ppm) δ: 32.50 (CH2), 126.53, 128.84, 129.07, 130.00, 6 
132.87, 135.39, 137.69, 144.13 (CHarom.), 156.96 (N=CH), 165.49 (N-C=N), 171.79 (C=O). Anal. 7 
Calcd. For C16H13ClN4O3S2 (408.88): C, 47.00; H, 3.20; N, 13.70. Found: C, 47.08; H, 3.22; N, 8 
13.83.  9 
4-(2-(4-(Dimethylamino)benzylidene)hydrazono)-4-oxothiazolidin-3-yl)benzenesulfonamide (9b) 10 
Yield, 46%; m.p. 218-220 ˚C; IR, cm-1: 3317, 3263 (NH2), 3050 (CH arom.), 2920, 2895 (CH 11 
aliph.), 1697 (C=O), 1596 (C=N), 1370, 1162 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 2.97 (s, 6H, 12 
N(CH3)2), 4.09 (s, 2H, CH2), 7.21 (d, 2H, J= 8.63 Hz, CHarom.), 7.50 (s, 2H, SO2NH2), 7.56 (d, 2H, 13 
J= 8.71 Hz, CHarom.), 7.79 (d, 2H, J= 8.99 Hz, CHarom.), 7.94 (d, 2H, J= 9.21 Hz, CHarom.), 8.15 (s, 14 
1H, N=CH). 
13
C-NMR (DMSO-d6, ppm) δ: 30.57 (CH2), 39.92 (N(CH3)2), 110.96, 112.96, 121.17, 15 
126.39, 128.89, 134.08, 136.75, 151.26 (CHarom.), 144.09 (N=CH), 165.80 (N-C=N), 174.79 (C=O). 16 
Anal. Calcd. For C18H19N5O3S2 (417.51): C, 51.78; H, 4.59; N, 16.77. Found: C, 51.89; H, 4.62; N, 17 
16.89.  18 
General procedures for the synthesis of ethyl 2-(4-(substituted)benzylidene)hydrazono)-4-oxo-3-(4-19 
sulfamoylphenyl)thiazolidine-5-carboxylates (10a,b)  20 
10 mmol of diethylbromomalonate and a catalytic amount of anhydrous sodium acetate were added 21 
to a solution of compound 8a or 8b (10 mmol) in glacial acetic acid (20 mL). The mixture was 22 
refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered 23 
off and crystallized from ethanol to give the corresponding 1,3-thiazolidin-4-one derivatives 10a,b.  24 
18 
 
Ethyl 2-(4-chlorobenzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)thiazolidine-5-carboxylate 1 
(10a) 2 
Yield, 48%; m.p. 159-161 ˚C; IR, cm-1: 3359, 3265 (NH2), 3092 (CH arom.), 2980, 2890 (CH 3 
aliph.), 1739, 1619 (2C=O), 1580 (C=N), 1380, 1162 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.23 (t, 4 
3H, J= 7.22 Hz, CH3), 4.21 (q, 2H, J= 7.16 Hz, CH2), 4.33 (s, 1H, CH), 7.64 (d, 2H, J= 8.71 Hz, 5 
CHarom.), 7.66 (s, 2H, SO2NH2, exchangeable with D2O), 7.81 (d, 2H, J= 8.69 Hz, CHarom.), 7.97 (d, 6 
2H, J= 8.98 Hz, CHarom.), 8.07 (d, 2H, J= 8.95 Hz, CHarom.), 8.50 (s, 1H, N=CH). 
13
C-NMR 7 
(DMSO-d6, ppm) δ: 13.56 (CH3), 25.46 (HC-C=O), 62.01 (CH2), 126.58, 128.89, 129.12, 130.12, 8 
132.93, 135.45, 137.73, 144.18 (CHarom.), 148.03 (N=CH), 155.21 (N-C=N), 164.21 9 
(COOCH2CH3), 171.89 (C=O). Anal. Calcd. For C19H17ClN4O5S2 (480.95): C, 47.45; H, 3.56; N, 10 
11.65. Found: C, 47.59; H, 3.60; N, 11.79.  11 
Ethyl 2-(4-(dimethylamino)benzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)-thiazolidine-5-12 
carboxylate (10b)  13 
Yield, 40%; m.p. 180-182 ˚C; IR, cm-1: 3352, 3260 (NH2), 3075 (CH arom.), 2980, 2891 (CH 14 
aliph.), 1725, 1612 (2C=O), 1592 (C=N), 1368, 1196 (SO2). 
1
H-NMR (DMSO-d6, ppm) δ: 1.18 (t, 15 
3H, J= 7.51 Hz, CH3), 2.86 (s, 6H, N(CH3)2), 4.11 (q, 2H, J= 7.49 Hz, CH2), 4.29 (s, 1H, CH), 7.07 16 
(d, 2H, J= 8.80 Hz, CHarom.), 7.31 (s, 2H, SO2NH2), 7.53 (d, 2H, J= 8.90 Hz, CHarom.), 7.62 (d, 2H, 17 
J= 9.10 Hz, CHarom.), 7.93 (d, 2H, J= 8.68 Hz, CHarom.), 8.18 (s, 1H, N=CH). 
13
C-NMR (DMSO-d6, 18 
ppm) δ: 13.93 (CH3), 29.90 (N(CH3)2), 39.96 (HC-C=O), 60.71 (CH2), 106.88, 107.70, 110.01, 19 
125.87, 127.44, 129.49, 132.08, 148.14 (CHarom.), 145.85 (N=CH), 188.66 (COOCH2CH3), 189.20 20 
(C=O). Anal. Calcd. For C21H23N5O5S2 (489.57): C, 51.52; H, 4.74; N, 14.31. Found: C, 51.63; H, 21 
4.79; N, 14.42.  22 
19 
 
General procedures for the synthesis of 2-(2-(4-(substituted)benzylidene)hydrazono)-4-oxo-3-(4-1 
sulfamoylphenyl)thiazolidin-5-yl)acetic acids (11a,b)  2 
10 mmol of maleic anhydride was added to a solution of compound 8a or 8b (10 mmol) in glacial 3 
acetic acid (20 mL). The mixture was refluxed for 24 h and left to cool then poured into crushed 4 
ice. The formed precipitate was filtered off and crystallized from ethanol to give the corresponding 5 
1,3-thiazolidin-4-one derivatives 11a,b. 6 
2-(-2-(4-Chlorobenzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)thiazolidin-5-yl)acetic acid 7 
(11a) 8 
Yield, 39%; m.p. 229-231 ˚C; IR, cm-1: 3353, 3256 (NH2), 3111 (OH), 3061 (CH arom.), 2933, 9 
2860 (CH aliph.), 1705, 1699 (2C=O), 1617 (C=N), 1385, 1160 (SO2). 
1
H-NMR (DMSO-d6, ppm) 10 
δ: 3.10 (d, 2H, J= 6.50 Hz, CH2), 4.58 (t, 1H, J= 6.87 Hz, CH), 7.45 (d, 2H, J= 8.88 Hz, CHarom.), 11 
7.57 (s, 2H, SO2NH2, exchangeable with D2O), 7.61 (d, 2H, J= 8.92 Hz, CHarom.), 7.76 (d, 2H, J= 12 
8.51 Hz, CHarom.), 7.98 (d, 2H, J= 8.59 Hz, CHarom.), 8.36 (s, 1H, N=CH), 10.86 (s, 1H, OH). 
13
C-13 
NMR (DMSO-d6, ppm) δ: 21.03 (CH2), 42.50 (CH), 126.43, 128.96, 129.32, 130.00, 132.89, 14 
135.35, 137.82, 144.13 (CHarom.), 156.83 (N=CH), 171.97 (N-C=N), 173.65 (C=O), 173.90 (C=O). 15 
Anal. Calcd. For C18H15ClN4O5S2 (466.92): C, 46.30; H, 3.24; N, 12.00. Found: C, 46.42; H, 3.26; 16 
N, 12.14.  17 
2-(2-(4-(Dimethylamino)benzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)thiazolidin-5-18 
yl)acetic acid (11b) 19 
Yield, 32%; m.p. 159-161 ˚C; IR, cm-1: 3362, 3226 (NH2), 3120 (OH), 3052 (CH arom.), 2914, 20 
2865 (CH aliph.), 1709, 1695 (2C=O), 1593 (C=N), 1371, 1154 (SO2). 
1
H-NMR (DMSO-d6, ppm) 21 
δ: 2.96 (s, 6H, N(CH3)2), 3.11 (d, 2H, J= 6.59 Hz, CH2), 4.55 (t, 1H, J= 6.88 Hz, CH), 6.72 (d, 2H, 22 
J= 8.61 Hz, CHarom.), 7.52 (s, 2H, SO2NH2), 7.56 (d, 2H, J= 8.99 Hz, CHarom.), 7.74 (d, 2H, J= 9.01 23 
Hz, CHarom.), 7.96 (d, 2H, J= 8.70 Hz, CHarom.), 8.15 (s, 1H, N=CH), 10.75 (s, 1H, OH). 
13
C-NMR 24 
20 
 
(DMSO-d6, ppm) δ: 36.74 (CH2), 39.76 (N(CH3)2), 42.45 (CH), 111.53, 121.08, 126.41, 128.80, 1 
137.90, 143.91, 151.94 161.04 (CHarom.), 158.14 (N=CH), 171.65 (N-C=N), 173.34 (C=O), 173.86 2 
(C=O). Anal. Calcd. For C20H21N5O5S2 (475.54): C, 50.51; H, 4.45; N, 14.73. Found: C, 50.63; H, 3 
4.49; N, 14.86.  4 
 5 
X-ray crystallography 6 
Suitable crystals for X-ray single crystal diffraction were selected, coated in perfluoropolyether oil, 7 
and mounted on MiTeGen sample holders. Diffraction data of the sample were collected on a 8 
Nonius Kappa three circle diffractometer utilizing mirror monochromated MoKα radiation (λ = 9 
0.71073 Å) from a rotating anode tube run at 50 V and 30 mA. The diffractometer is equipped with 10 
a Bruker ApexII area detector and an open flow N2 Cryoflex II (Bruker) device. Measurements 11 
were performed at 100 K. For data reduction, the Bruker Apex2 software suite (Bruker AXS), was 12 
used. Using Olex2 (Dolomanov et al., 2009), the structure was solved with the ShelXS-97 13 
(Sheldrick, 2008) structure solution program using direct methods solution method. The model was 14 
refined with XL (Sheldrick, 2008) using Least Squares minimization. All non-hydrogen atom 15 
positions were located from the Fourier maps and refined anisotropically. Hydrogen atom positions 16 
were calculated using a riding model in geometric positions and refined isotropically. 17 
Cambridge Structural Database (CSD) number: CCDC 1004668. 18 
Crystal Data: C10H11N3O3S2, Mr = 285.34, triclinic, P-1, a = 9.8121(4) Å, b = 10.2076(5) Å, c = 19 
24.6210(10) Å, α = 83.992(2)°, β = 82.035(2)°, γ = 77.674(2)°, V = 2378.71(18) Å3, T = 100 K, Z = 20 
8, Z' = 4, µ (MoKα) = 0.451, 21120 reflections measured, 9859 unique (Rint = 0.0337) which were 21 
used in all calculations. The final wR2 was 0.2419 (all data) and R1 was 0.0747 (I≥2σ(I)). 22 
21 
 
Antibacterial activity 1 
Pure compounds were dissolved in sufficient volume of dimethylsulfoxide (DMSO) to make a final 2 
concentration of 20 mM. Bacterial strains (S. aureus NCTC 8325, S. aureus HG001, S. aureus 3 
MA12, S. aureus RN1, S. aureus Xen29, S. epidermidis RP62A, S. epidermidis 195, S. epidermidis 4 
047, E. faecalis JH212, E. faecium 6413, E.coli 536, P. aeruginosa, Y. pestis KUMA, and Y. 5 
pseudotuberculosis 252 01A) were cultivated overnight at 37 °C (30 °C for Yersinia) in Luria-6 
Bertani medium (per liter: 5 g NaCl, 5 g yeast extract, 10 g tryptone) in a shaking incubator.  7 
On the next day, the overnight culture was diluted 1:100 in Müller-Hinton broth (23 g per Liter) 8 
and again incubated until the cells reached the exponential growth phase. Approximately, 1x10
5
 9 
cells/mL were incubated with various concentrations of the compounds (40, 20, 10, 5, 2.5, 1.25, 10 
0.625, and 0.3125 µM) at 37°C for 18 h (30°C for 48 h for Yersinia) to make a final volume of 200 11 
µL in a 96-well plate. The final concentration of DMSO was 0.8% in each well. 12 
After incubation, the optical density of the cultures was determined at 550 nm wavelength using an 13 
ELISA microplate reader (MutlisKan Ascent, Thermo Fisher Scientific) with respect to the control 14 
without bacteria. The lowest concentration of a tested compound, where no bacterial growth is 15 
detectable, was determined as minimum inhibitory concentration (MIC). From substances whose 16 
MIC is less than 20 µM, the overnight cultures from the wells where no bacterial growth was 17 
detected were plated on LB agar plates and incubated again overnight. The compound 18 
concentration, at which no growth of the bacteria was detectable, was determined as the minimum 19 
bactericidal concentration (MBC). 20 
Inhibition of biofilm formation 21 
Quantitative biofilm of S. epidermidis RP62A (ATCC 32984) measurement was done in a 22 
microtiter assay. Bacteria were grown overnight in Trypticase Soy Broth / 0.25% glucose (Becton 23 
Dickinson). 100 µL of a 1:200 dilution of the overnight culture, with fresh medium, was transferred 24 
22 
 
to 96-well tissue culture plates (Greiner, Nürtingen, Germany) added to 100 µL of a serial dilution 1 
of the test compounds in medium. Each compound concentration was measured in five replicates. 2 
The DMSO concentration in all wells was 0.8%.   3 
Following overnight incubation at 37°C, the optical density at 550 nm (OD600) of the bacteria was 4 
measured and the cultures were poured out. The plates were washed three times with phosphate-5 
buffered saline and the remaining bacteria were fixed by air drying at 60 °C. After staining with 6 
0.4% crystal violet solution, the optical density of the adherent biofilm was determined at 490 nm. 7 
Values >0.120 at compound concentrations, with no effect on the bacterial growth in culture, were 8 
regarded as biofilm positive. 9 
 10 
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 20 
 21 
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Scheme 1: Synthesis of compounds 3a-c, 4a-c and 5a-c.  1 
 2 
 3 
 4 
 5 
 6 
Reagents and conditions: (i) R-NCS / EtOH / TEA / reflux 24 h. (ii) ClCH2COOH / AcOH / 7 
anhydrous CH3COONa / reflux 24 hr. (iii) Diethylbromomalonate / AcOH / anhydrous CH3COONa 8 
/ reflux 24 h. (iv) Maleic anhydride / AcOH / reflux 24 h.   9 
  10 
 11 
 12 
 13 
 14 
 15 
 16 
27 
 
Scheme 2: Synthesis of compounds 9a,b , 10a,b and 11a,b.  1 
 2 
 3 
 4 
Reagents and conditions: (i) CSCl2 / H2O / HCl / stirring RT / 2 h. (ii) NH2NH2.H2O / isopropanol / 5 
stirring RT / 2 h. (iii) Ar-CHO / MeOH / reflux 5 h. (iv) ClCH2COOH / AcOH / anhydrous 6 
CH3COONa / reflux 24 hr. (v) Diethylbromomalonate / AcOH / anhydrous CH3COONa / reflux 24 7 
h. (vi) Maleic anhydride / AcOH / reflux 24 h. 8 
 9 
 10 
 11 
 12 
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 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
Figure 1:   Molecular structure of compound 3a as determined by X-ray single crystal diffraction: 11 
a) molecule and naming scheme and b) assymetric unit with hydrogen bonds. Element (colour): 12 
Carbon (grey), oxygen (red), nitrogen (blue), sulfur (yellow), hydrogen (light grey). Atomic 13 
displacement parameters are drawn at 50% probability. 14 
 15 
 16 
 17 
 18 
(a) Single molecule and naming scheme. 
(b) Asymmetric unit with indication of hydrogen 
bonds. 
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 1 
Table 1:  Antibacterial activity of the tested compounds 4a and 4c 2 
 3 
 Tested bacterial strain 
Compound 4a Compound 4c Gentamycin Tetracycline 
MIC
*
 
(µM) 
MBC
**
 
(µM) 
MIC 
(µM) 
MBC 
(µM) 
MIC 
(µM) 
MIC 
(µM) 
G
ra
m
-p
o
si
ti
v
e
 
S. aureus 8325 10 >40 5 >40 0.21 NT
***
 
S. aureus HG001 10 >40 5 >40 NT NT 
S. aureus MA12 10 >40 5 >40 NT NT 
S. aureus RN1 40 >40 20 >40 NT NT 
S. aureus Xen29 10 >40 5 >40 NT NT 
S. epidermidis RP62A 5 >40 5 >40 NT 0.83 
S. epidermidis 195 10 >40 10 >40 NT NT 
S. epidermidis 047 5 >40 2.5 >40 NT NT 
E. faecalis JH212 5 10 2.5 5 26.2 NT 
E. faecium 6413 >40 >40 >40 >40 NT 0.83 
G
ra
m
-n
eg
a
ti
v
e E. coli 536 >40 >40 >40 >40 0.83 NT 
P. aeruginosa >40 >40 >40 >40 3.4 NT 
Y. pestis KUMA 10 >40 5 >40 1.7 NT 
Y. pseudotuberculosis 252 01A >40 >40 >40 >40 1.7 NT 
* MIC: Minimal Inhibitory Concentration 4 
** MBC: Minimal Bactericidal Concentration 5 
*** NT: Not tested 6 
